Skip to main content

What the FDA labels say about taking them together

Anagrelide and milrinone

Anagrelide's FDA label of April 8, 2026 names milrinone in its drug interactions section; the milrinone label PlainMeds reads does not name anagrelide. The anagrelide label: “Avoid use of drug products with similar properties such as inotropes and other PDE3 inhibitors.”

Check it at the source: the anagrelide FDA label on DailyMed (effective April 8, 2026, Takeda Pharmaceuticals America, Inc.); the milrinone FDA label on DailyMed (effective June 13, 2026, Shandong New Time Pharmaceutical Co., Ltd.).

What does the anagrelide label say about milrinone?

Anagrelide label, drug interactions

Avoid use of drug products with similar properties such as inotropes and other PDE3 inhibitors (e.g., cilostazol, milrinone) [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2) ].

Source: FDA drug label (Agrylin), Takeda Pharmaceuticals America, Inc., effective April 8, 2026 (SPL set cb960074-99c1-4a73-941f-f0644a7ec219), via openFDA; the full label on DailyMed

What does the milrinone label say about anagrelide?

Milrinone's label (effective June 13, 2026) does not name anagrelide in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Milrinone Lactate), Shandong New Time Pharmaceutical Co., Ltd., effective June 13, 2026 (SPL set 0fdaee3c-2144-4ca7-9868-54d251f468c0), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

3Anagrelide generic labelers
13Milrinone generic labelers
AnagrelideMilrinone
Labeled forn/aHeart failure
Boxed warningNoNo
Pharmacy cost (NADAC)$0.729 per capsule 0.5 mg capsulen/a
Shortage nowA presentation being discontinuedNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?